Trevena, Inc. TRVN

Trevena (TRVN) stock could find support soon, prompting a buy recommendation. The article suggests a moderately noticeable influence on TRVN's future and market performance.

Trevena, Inc. reported financial results for Q3 2024, including a net loss of $4.9 million. The company received non-dilutive financing, underwent a reverse stock split, and was delisted from Nasdaq. Cost-cutting measures led to the termination of three senior executives and the resignation of certain directors. Trevena continues to review strategic alternatives for its pipeline assets. Trevena's financial results, delisting from Nasdaq, termination of executives, and ongoing strategic review are expected to significantly impact the company's future trajectory.

Trevena, Inc. received a Nasdaq delisting notification due to failure to comply with minimum stockholder's equity requirement. Delisting from Nasdaq and potential move to OTC market will significantly impact Trevena's future trading and market performance.

Trevena, Inc. reports second quarter 2024 results, including positive preclinical data for TRV045 and completion of $12 million financing. The company also continues strategic review for OLINVYK. Positive preclinical data for TRV045 and completion of financing could significantly impact Trevena's future development and market performance.

Sagimet Biosciences appoints Anne Phillips and Jennifer Jarrett to its board of directors as they prepare for Phase 3 clinical development of denifanstat in MASH. The addition of industry leaders to the board and the advancement of denifanstat into late-stage development are significant moves that could impact Sagimet's future trajectory.

Trevena, Inc. receives $2M non-dilutive financing tranche and $10M reduction in liabilities from ex-US royalty financing amendment with R-Bridge Healthcare Fund, L.P. The amendment to the ex-US royalty financing and potential future tranches based on OLINVYK milestones could significantly impact Trevena's financial position and commercialization efforts.

Trevena, Inc. announces preclinical data on TRV045 showing potential for sustained analgesic effect in neuropathic pain model and statistically significant anti-seizure activity in epilepsy models. The article describes significant potential impact on Trevena, Inc.'s future drug development and market positioning.

Trevena, Inc. reports first quarter 2024 results and provides business update, highlighting progress in TRV045 program and ongoing clinical studies. The article discusses significant advancements in TRV045 program and ongoing clinical studies, which could have a major impact on Trevena, Inc.'s future performance and market positioning.

Trevena, Inc. held their Q1 2023 earnings call, discussing OLINVYK approval in China, TRV045 progress, and financial results. Significant impact expected on future performance due to upcoming milestones, strategic shifts, and potential value drivers discussed.

Trevena, Inc. reports financial results for Q4 2023, focuses on TRV045 development, reduces OLINVYK commercial support, and explores strategic alternatives for OLINVYK. The company's decision to focus on TRV045 development and explore alternatives for OLINVYK could significantly impact its future product portfolio and market positioning.

Trevena, Inc. closed a $4 million private placement and warrant exercise. The private placement and warrant exercise may moderately influence Trevena, Inc.'s financial performance and strategic positioning.

Trevena Inc. announces $4 million private placement and warrant exercise. The private placement and warrant exercise are significant financial moves that could impact Trevena's future trajectory and market performance.

Trevena to present TRV045 at ACNP 62nd Annual Meeting. Presentation at a major conference may influence competitive positioning.

Trevena Inc. awarded national group purchasing agreement for OLINVYK with Premier, Inc. The agreement with Premier, Inc. may moderately influence Trevena, Inc.'s financial performance and competitive positioning.

Trevena, Inc. announced acceptance of an abstract on the use of OLINVYK in patients with acute burn injuries at the 2024 ABA annual meeting. The study results may moderately influence Trevena, Inc.'s future product development and market positioning.

Trevena's third quarter 2023 earnings show revenues beating expectations while EPS lags. The financial results and growth forecasts indicate a moderately noticeable influence on Trevena's future performance.

Trevena, Inc. reported significant milestones in Q3 2023, including positive results for TRV045 in chronic pain and epilepsy studies. The positive results for TRV045 in chronic pain and epilepsy studies are expected to have a significant impact on Trevena, Inc.'s future and market performance.

Trevena, Inc. reports positive results for TRV045 studies and receives $15 million tranche from ex-US royalty-based financing. Company to host conference call. Positive results from TRV045 studies and financing boost expected to significantly impact Trevena's future trajectory.

Trevena, Inc. to release third quarter 2023 financial results on November 14, 2023. Financial results release and conference call may moderately influence market sentiment and financial performance.

Trevena, Inc. reports favorable safety and tolerability data for TRV045 from proof-of-concept studies. Positive safety and tolerability data for TRV045 could significantly impact Trevena's future development and market performance.

Trevena, Inc. completes initial analysis of OLINVYK continuous respiratory monitoring data from VOLITION study and will present findings at American Society of Anesthesiologists Conference. The completion of the analysis and presentation at a major conference can significantly impact Trevena, Inc.'s future performance and market perception.

Trevena, Inc. receives $15 million tranche from ex-US royalty-based financing triggered by first commercial sale of OLINVYK in China. New respiratory data from VOLITION study expected in 3Q 2023. Three OLINVYK abstracts accepted for presentation at ASA Meeting in 4Q 2023. Company to participate in HC Wainwright conference and hold conference call on TRV045 Proof-of-Concept Data. Significant impact likely on future and performance with key milestones achieved and potential market expansion in China.

Trevena, Inc. announces positive preliminary data from two Phase 1 proof-of-concept studies of TRV045 for neuropathic pain and CNS disorders. The positive data from the studies could significantly impact Trevena's future drug development and market performance.

Trevena, Inc. reports Q2 2023 results and provides business update, including progress on TRV045 studies, new respiratory data, and financial results. Significant impact expected on future performance due to progress on key studies, new data, and financial results.

Trevena, Inc. appoints Mark Corrigan, M.D. to Board of Directors. Dr. Corrigan's extensive industry experience and expertise in neuroscience could significantly impact Trevena's strategic direction and pipeline development.

Trevena, Inc. announces new data showing reduced cost per admission and hospital stay for OLINVYK-treated patients compared to those treated with other IV opioids. The significant cost reduction and improved outcomes for OLINVYK-treated patients are expected to have a major impact on Trevena, Inc.'s future performance.

Trevena, Inc. receives $3 million milestone payment for Chinese approval of OLINVYK from partner in China Jiangsu Nhwa Pharmaceutical. Receiving milestone payment and potential non-dilutive financing from China partner indicates significant impact on future financial performance and market positioning.

Trevena, Inc. regains compliance with Nasdaq listing rules and reaffirms near-term milestones for its CNS disorder-focused medicines. The news of regaining compliance and reaffirming milestones is expected to have a significant impact on Trevena, Inc.'s future performance and market positioning.